To include your compound in the COVID-19 Resource Center, submit it here.

Novo launches Ozempic and Fiasp in U.S.

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) launched in the U.S. Ozempic semaglutide (NN9535) to treat Type II diabetes

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE